ThyCa survey on radiation safety during most recent I-131 treatment |
1. Thyroid Cancer Survivors
Dear Thyroid Cancer Survivor:
This survey is to obtain information regarding radioiodine (I-131) treatments.
This survey should take 10-15 minutes and your participation and responses are completely anonymous. The results of the survey will be made available to you at the end of the survey.
This survey is to obtain information regarding radioiodine (I-131) treatments.
This survey should take 10-15 minutes and your participation and responses are completely anonymous. The results of the survey will be made available to you at the end of the survey.
You may have participated in a similar survey previously. The objective of this survey study is to evaluate whether there has been a change in medical practice on the release of patients treated with I-131 after the 2011 Nuclear Radiation Commission (NRC) Regulatory Issue Summary publication that strongly discouraged patients from residing in locations other than a private residence.
If you are a guardian of a minor or another individual who received an I-131 treatment, please complete this survey for that minor or other individual for whom you are the guardian.
In advance, thank you for your participation.
Yours truly,
The ThyCa Survey Committee
Committee Members are:
Gary Bloom, Executive Director and Co-Founder
ThyCa: Thyroid Cancer Survivors' Association, Inc.
Washington, D.C.
Douglas Van Nostrand, MD, FACP, FACNP
Committee Chair
Director, Division of Nuclear Medicine
Washington Hospital Center
Professor of Medicine, Georgetown University Hospital Center
Washington, D. C.
Matthew D. Ringel, M.D.
Professor of Medicine
Divisions of Endocrinology and Oncology
Co-Director, Thyroid Cancer Unit
The Ohio State University College of Medicine& Arthur G. James Comprehensive Cancer Center
Columbus, OH
Richard J. Vetter, Ph.D., CHP
Director of Safety
Professor of Biophysics
Mayo Clinic
Rochester, Minnesota
Elizabeth A. Carter, PhD, MPH
Department of Epidemiology and Statistics
MedStar Research Institute
Di Wu, MD
Nuclear Medicine Research Coordinator
Washington Hospital Center
Washington, D.C.
Financial Disclosure: None of the members of this survey committee have received any funding from any organization for the development of this survey.
If you are a guardian of a minor or another individual who received an I-131 treatment, please complete this survey for that minor or other individual for whom you are the guardian.
In advance, thank you for your participation.
Yours truly,
The ThyCa Survey Committee
Committee Members are:
Gary Bloom, Executive Director and Co-Founder
ThyCa: Thyroid Cancer Survivors' Association, Inc.
Washington, D.C.
Douglas Van Nostrand, MD, FACP, FACNP
Committee Chair
Director, Division of Nuclear Medicine
Washington Hospital Center
Professor of Medicine, Georgetown University Hospital Center
Washington, D. C.
Matthew D. Ringel, M.D.
Professor of Medicine
Divisions of Endocrinology and Oncology
Co-Director, Thyroid Cancer Unit
The Ohio State University College of Medicine& Arthur G. James Comprehensive Cancer Center
Columbus, OH
Richard J. Vetter, Ph.D., CHP
Director of Safety
Professor of Biophysics
Mayo Clinic
Rochester, Minnesota
Elizabeth A. Carter, PhD, MPH
Department of Epidemiology and Statistics
MedStar Research Institute
Di Wu, MD
Nuclear Medicine Research Coordinator
Washington Hospital Center
Washington, D.C.
Financial Disclosure: None of the members of this survey committee have received any funding from any organization for the development of this survey.